In a report released yesterday, Peter Welford from Jefferies maintained a Hold rating on Qiagen (QGEN – Research Report), with a price target of EUR47.00. The company’s shares closed last Tuesday at $47.84.
According to TipRanks.com, Welford is a 5-star analyst with an average return of 19.2% and a 62.6% success rate. Welford covers the Healthcare sector, focusing on stocks such as Roche Holding AG, AstraZeneca, and Sanofi.
Qiagen has an analyst consensus of Hold, with a price target consensus of $57.92.
Based on Qiagen’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $571 million and net profit of $213 million. In comparison, last year the company earned revenue of $413 million and had a net profit of $44.93 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.